Cue Biopharma, Inc.
CUE Real Time Price USDRecent trades of CUE by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CUE's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
CUE Revenue by Segment or Geography
New patents grants
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 31, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 26, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 19, 2024
-
Patent Title: Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof Jul. 09, 2024
-
Patent Title: T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof Jun. 11, 2024
-
Patent Title: Methods for modulating an immune response May. 28, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof May. 21, 2024
-
Patent Title: Methods for modulating an immune response Apr. 16, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Feb. 20, 2024
-
Patent Title: Multimeric t-cell modulatory polypeptides and methods of use thereof Jan. 23, 2024
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 26, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 26, 2023
-
Patent Title: Methods for modulating an immune response Sep. 26, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 29, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 25, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides Jul. 18, 2023
-
Patent Title: Tgf-β polypeptides Jul. 04, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 20, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
-
Patent Title: Methods for modulating an immune response Oct. 25, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 02, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 05, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jun. 28, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Sep. 14, 2021
-
Patent Title: Methods for modulating an immune response Aug. 31, 2021
-
Patent Title: Methods for modulating an immune response Feb. 23, 2021
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Feb. 23, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CUE
Number of mentions of CUE in WallStreetBets Daily Discussion
Recent picks made for CUE stock on CNBC
ETFs with the largest estimated holdings in CUE
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CUE stock a Buy, Sell, or Hold?
- What is the price target for $CUE stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CUE stock?
- Who owns the most shares of $CUE stock?
- What funds own $CUE stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CUE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.